XBIT
XBiotech Inc
stockNASDAQ
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.15 | 2026-09-28 | +1.86% | -1.455 |
| 1M | 2.20 | 2026-09-04 | -0.46% | 0.449 |
| 3M | 2.41 | 2026-07-06 | -9.13% | 0.005 |
| 6M | 2.32 | 2026-04-06 | -5.60% | 0.204 |
| 1Y | 2.64 | 2025-10-03 | -17.05% | 0.525 |
| 2Y | 7.48 | 2024-10-04 | -70.72% | — |
| 5Y | 12.99 | 2021-10-04 | -83.14% | 1.005 |
XBiotech Inc (NASDAQ:XBIT) stock price today is $2.19, and today's volume is 25,237. XBIT is down 0.455% today. The 30 day average volume is 44,596. XBIT market cap is $66.77M with 30.49M shares outstanding.